Five Prime to sell 4 million shares in IPO between $12.00 and $14.00

Proceeds used for Phase 1 clinical trials, general corporate purposes

By Devika Patel

Knoxville, Tenn., Sept. 4 - Five Prime Therapeutics, Inc. will sell 4 million common shares in its initial public sale with a 30-day greenshoe option of 600,000 additional shares, according to a Form S-1 filed Wednesday with the Securities and Exchange Commission. The deal was announced on July 26.

The stock is expected to be priced between $12.00 and $14.00 per share.

Jefferies, BMO Capital Markets and Wells Fargo Securities are the joint bookrunning managers. Guggenheim Securities is the co-manager.

Proceeds will be used for a Phase 1 clinical trial of FPA008, a Phase 1 clinical trial of FPA144, working capital and general corporate purposes.

The clinical-stage biotechnology company is based in South San Francisco, Calif. The company intends to list its common stock on the Nasdaq exchange under the symbol "FPRX."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.